AR093734A1 - Un metodo para tratar la enfermedad de lyme - Google Patents
Un metodo para tratar la enfermedad de lymeInfo
- Publication number
- AR093734A1 AR093734A1 ARP130100013A ARP130100013A AR093734A1 AR 093734 A1 AR093734 A1 AR 093734A1 AR P130100013 A ARP130100013 A AR P130100013A AR P130100013 A ARP130100013 A AR P130100013A AR 093734 A1 AR093734 A1 AR 093734A1
- Authority
- AR
- Argentina
- Prior art keywords
- cefovecin
- disease
- dose
- antibiotic agent
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para tratar la enfermedad de Lyme y/o una infección por Borrelia en animales que comprende administrar a un animal que lo necesita una cantidad terapéuticamente efectiva de cefovecina. Reivindicación 4: El método de la reivindicación 3, caracterizado porque la segunda dosis de cefovecina es administrada aproximadamente 10 a 13 días después de la primera dosis de cefovecina. Reivindicación 5: El método de la reivindicación 1, caracterizado porque la cefovecina es administrada por inyección subcutánea. Reivindicación 8: El método de la reivindicación 7, caracterizado porque el animal no humano es canino, felino, bovino, equino, o ave de corral. Reivindicación 14: El método de la reivindicación 13, caracterizado porque la administración de al menos otro agente antibiótico es concomitante o secuencial. Reivindicación 15: El método de la reivindicación 13, caracterizado porque el otro agente antibiótico se selecciona de doxiciclina, amoxicilina, azitromicina, oxitetraciclina, minociclina, y ceftriaxona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261582742P | 2012-01-03 | 2012-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093734A1 true AR093734A1 (es) | 2015-06-24 |
Family
ID=47459202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100013A AR093734A1 (es) | 2012-01-03 | 2013-01-02 | Un metodo para tratar la enfermedad de lyme |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9265771B2 (es) |
| EP (1) | EP2800570A1 (es) |
| JP (1) | JP2013139443A (es) |
| AR (1) | AR093734A1 (es) |
| AU (1) | AU2012363652A1 (es) |
| BR (1) | BR112014016575A8 (es) |
| CA (1) | CA2860574C (es) |
| MX (1) | MX2014008194A (es) |
| WO (1) | WO2013103531A1 (es) |
| ZA (1) | ZA201405451B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017034984A1 (en) * | 2015-08-21 | 2017-03-02 | The Johns Hopkins University | Identification of additional anti-persister activity against borrelia burgdorferi from an fda drug library |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2568959A2 (en) * | 2010-05-14 | 2013-03-20 | Mahmut Bilgic | Formulations comprising a third generation cephalosporin and clavulanic acid |
-
2012
- 2012-12-20 EP EP12808658.4A patent/EP2800570A1/en not_active Withdrawn
- 2012-12-20 US US14/370,239 patent/US9265771B2/en active Active
- 2012-12-20 MX MX2014008194A patent/MX2014008194A/es unknown
- 2012-12-20 CA CA2860574A patent/CA2860574C/en not_active Expired - Fee Related
- 2012-12-20 AU AU2012363652A patent/AU2012363652A1/en not_active Abandoned
- 2012-12-20 BR BR112014016575A patent/BR112014016575A8/pt not_active Application Discontinuation
- 2012-12-20 WO PCT/US2012/070753 patent/WO2013103531A1/en active Application Filing
- 2012-12-28 JP JP2012286979A patent/JP2013139443A/ja active Pending
-
2013
- 2013-01-02 AR ARP130100013A patent/AR093734A1/es unknown
-
2014
- 2014-07-23 ZA ZA2014/05451A patent/ZA201405451B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013139443A (ja) | 2013-07-18 |
| MX2014008194A (es) | 2015-03-19 |
| US9265771B2 (en) | 2016-02-23 |
| BR112014016575A8 (pt) | 2017-07-04 |
| WO2013103531A1 (en) | 2013-07-11 |
| CA2860574C (en) | 2017-01-03 |
| AU2012363652A1 (en) | 2014-07-24 |
| US20140343003A1 (en) | 2014-11-20 |
| ZA201405451B (en) | 2015-12-23 |
| EP2800570A1 (en) | 2014-11-12 |
| CA2860574A1 (en) | 2013-07-11 |
| BR112014016575A2 (pt) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064363A1 (es) | Tratamiento de cerdos con el antigeno pcv | |
| AR057904A1 (es) | Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide | |
| BR112015028692A8 (pt) | agente preventivo ou terapêutico para mastite de animal ruminante | |
| PE20190351A1 (es) | Agente terapeutico del sindrome de hunter y metodo de tratamiento | |
| AR092713A1 (es) | Composiciones y metodos de uso de un compuesto para el control de la inapetencia | |
| AR093734A1 (es) | Un metodo para tratar la enfermedad de lyme | |
| US20110144048A1 (en) | Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess | |
| AR019579A1 (es) | USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS | |
| Bloom | Use of veterinary pharmaceuticals in the United States | |
| Bentz | Clinical pharmacology of the equine musculoskeletal system | |
| CN105497072B (zh) | 一种防治种猪裂蹄病的药毯 | |
| RU2012129115A (ru) | Способ лечения острых послеродовых эндометритов у коров | |
| CN103230583A (zh) | 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法 | |
| Nath et al. | Bilateral hygroma in a Great Dane dog and its surgical management | |
| RU2013150192A (ru) | Метапневмовирус птиц в онколизисе | |
| WO2016071446A1 (en) | A veterinary injectable formulation | |
| WO2009002922A3 (en) | Single dose roxithromycin | |
| Majid et al. | Care and management of wound in animals | |
| CL2018003269A1 (es) | Ácidos carboxílicos para aplicación en la primera infancia. | |
| Das et al. | Tetanus in a buffalo calf and its therapeutic management | |
| RU2521242C2 (ru) | Способ лечения пальцевого дерматита крупного рогатого скота | |
| RU2564948C1 (ru) | Способ лечения эндометритов у коров | |
| RU2552912C1 (ru) | Способ повышения биоцидного действия в отношении бактерий, вирусов, патогенных грибов антисептика-стимулятора дорогова асд-2ф | |
| RU2412704C1 (ru) | Способ лечения рожи свиней | |
| RU2698400C1 (ru) | Способ лечения депрессии у собак и кошек |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |